Alternatives to Travere Therapeutics

Biopharmaceutical company focused on developing and commercializing innovative treatments for rare neurological disorders.

Biopharmaceutical company focused on rare genetic diseases of obesity.

A commercial-stage biopharmaceutical company developing cell and gene therapies for rare diseases.

South Korean biopharmaceutical company developing novel biologics for cancer and rare diseases.

Biotechnology company focused on developing treatments for rare metabolic diseases.

Clinical-stage biotech company developing AAV gene therapies for rare and retinal diseases.

Biopharmaceutical company developing novel therapies for rare and ultra-rare genetic diseases.

Global biopharmaceutical company specializing in plasma-derived therapeutics for rare and serious conditions.

Global leader in animal health, providing innovative products and services for pets and livestock.

Ultiracer is an indoor cycling platform developed by RealDesignTech that offers brain-body balance training through real steering, weight shifting, and balance control, enhancing cognitive performance and fitness.

Biopharmaceutical company developing transformative medicines for patients with genetic diseases and cancers.

Japanese biopharmaceutical company developing biologics and gene therapies for CNS and rare diseases.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Clinical-stage biopharmaceutical company developing gene therapies for rare genetic diseases.

Biopharmaceutical company focused on developing RNA-targeted therapies for rare genetic diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.